TABLE 1

Extracellular in vitro susceptibility testing

First author [ref.]StrainStrains nMethodConcentration range μg·mL−1DrugspHMIC μg·mL−1MIC90 μg·mL−1Mean log10 reduction in viable counts
Bergmann [38]CI, MDR-TB5BAC1.0–8.0CLR>8
Cavalieri [36]CI, MDR-TB6BAC0.25–16CLR≥16
14-OH-CLR>16
Luna-Herrera [39]CI, MDR-TB5BAC0.06–16.0CLR4– ≥16
Stoffels [37]CI, MDR-TB16BAC2, 4, 8, 16CLR≤2– >16
Bosne-David [40]CI, MDR-TB14BAC4CLR>4
Hoffner [41]CI, MDR-TB17BAC2, 4, 8, 16CLR2– ≥16
ROX4– ≥16
AZI>16
Yew [42]CI, MDR-TB17BM-7H90.03–8.0CLR0.25– >8.0>8
ERY>8>8
AZI4.0– >8.0>8
Lu [43]CI, MDR-TB22PM2–128CLR64
Rastogi [44]CI, MDR-TB3BAC5–20CLR6.810–20
7.44–16
2VCE40CLR<1
Rastogi [45]CI, MDR-TB13BAC0.5, 1, 2, 4, 8, 16, 32, 64ROX6.832– >64
7.416– >32
PM0.5, 1, 2, 4, 8, 16, 32, 646.864– >64
CI, MDR-TB1VCE646.81
327.41–2
Umubyeyi [46]CI, MDR-TB69BAC4CLR<4
Falzari [47]H37Rv1MABA3–104CLR5.98
ROX26.79
AZI95.87
CETH3.06
TELI103.93
CI, MDR-TB3CLR2.0–32.0
Sato [48]Kurono MDR-TB1BM-7HSF0.5–128CLR20
Tomioka [49]Kurono MDR-TB1BMM?–25#CLR25
  • MIC: minimal inhibitory concentration; MIC90: MIC that inhibits 90% of the isolates or strains; CI: clinical isolate; MDR-TB: multidrug-resistant tuberculosis; BAC: Radiometric BACTEC TB 460; CLR: clarithromycin; 14-OH-CLR: 14-hydroxyclarithromycin; ROX: roxithromycin; AZI: azithromycin; BM-7H9: broth dilution method with 7H9 medium; ERY: erythromycin; PM: proportion method with Middlebrook 7H10 agar; VCE: viable count enumeration; MABA: microplate Alamar blue assay; CETH: cethromycin; TELI: telithromycin; BM-7HSF: broth dilution method with 7HSF medium; BMM: broth microdilution method using 7SHF medium. #: tested range described in the methods section.